Title: SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV.

Authors: Ilic V, Dunet V, Le Pape A, Buchs M, Kosinski M, Bischof Delaloye A, Gerber S, Prior JO

Journal: Nuklearmedizin. Nuclear medicine

Year: 2016 Sep 26

Issue: 55

Volume: 5

Pages: 203-8

DOI: 10.3413/Nukmed-0811-16-03

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
SPECT/CT study of bronchial deposition of inhaled particles in a human aerosol vaccination model against HPV

Vesna Ilic,¹ Vincent Dunet,¹ Alain Le Pape,²,³ Mikael Buchs,¹ Marek Kosinski,¹ Angelika Bischof Delaloye,¹ Stefan Gerber,⁴ John O. Prior¹

¹Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland; ²Research Center for Respiratory Diseases, INSERM U1100/EA 6305, François Rabelais University, Tours France; ³TAAM-CIPA, UPS 44, CNRS, Orléans, France. ⁴Gynecology Practice, Fribourg Switzerland

Running Head: SPECT/CT of bronchial deposition

Character count for main text: 19’943 characters (<22’000)
Character count for abstract: 1,777 characters (<1,800)
ENGLISH SUMMARY

Aims—Vaccination by aerosol inhalation can be used to efficiently deliver antigen against HPV to mucosal tissue, which is particularly useful in developing countries (simplicity of administration, costs, no need for cold chain). For optimal immunological response, vaccine particles should preferentially be delivered to proximal bronchial airways. We aimed at quantifying the deposition of inhaled particles in central airways and peripheral lung, and to assess administration biosafety.

Methods—Twenty healthy volunteers (13W/7M, aged 24±4y) performed a 10-min free-breathing inhalation of $^{99m}$Tc-stannous chloride colloid aerosol (450 MBq) in a buffer solution without vaccinal particles using an ultrasonic nebulizer (mass median aerodynamic diameter 4.2 µm) and a double mask inside a biosafety cabinet dedicated to assess environmental particle release. SPECT/CT and whole-body planar scintigraphy were acquired to determine whole-body and regional $C/P$ distribution ratio (central-to-peripheral pulmonary deposition counts). Using a phantom, SPECT sensitivity was calibrated to obtain absolute pulmonary activity deposited by inhalation.

Results—All participants successfully performed the inhalation that was well tolerated (no change in pulmonary peak expiratory flow rate, $P = 0.9$). It was environmentally safe (no activity released in the biosafety filter.)
1.3±0.6% (range 0.4–2.6%) of the total nebulizer activity was deposited in
the lungs with a C/P distribution ratio of 0.40±0.20 (range 0.15–1.14).

**Conclusion**—Quantification and regional distribution of inhaled particles in
an aerosolized vaccine model is possible using radioactive particles. This
will allow optimizing deposition parameters and determining the particles
charge for active-particles vaccination.

**KEYWORDS**
Aerosol inhalation; Pulmonary deposition; SPECT/CT; Tc-99m; Targeted
cache delivery; HPV.
ZUSAMMENFASSUNG


Die Ganzkörper Verteilung und der regionale C/P Verteilungskoeffizient (Quotient zentrale über periphere Lungenaktivität) wurden mittels der SPECT/CT und einer Ganzkörper-Szintigraphie bestimmt. Die SPECT
Empfindlichkeit wurde mittels eines Phantoms kalibriert, um die absolute inhalierte Aktivität in der Lunge zu bestimmen.

**Ergebnisse**—Die Inhalation wurde von allen Studienteilnehmern vollendet und gut vertragen (Peak Flow unverändert, \( P=0.9 \)). Der Biosicherheitsfilter war frei von Radioaktivität. 1.3±0.6% (0.4–2.6%) der Gesamtaktivität des Verneblers wurde in den Lungen gemessen, mit einem C/P Verteilungsquotienten von 0.40±0.20 (0.15–1.14).

**Schlussfolgerung**—Die Aufnahme und regionale Verteilung inhalierter Partikel können in einem Aerosol-Impf-Modell mittels radioaktiv markierter Partikel quantitativ bestimmte werden und so zur Optimierung der Parameter beitragen, die für Verteilung und Beladung von aktiven Impfstoff-Partikeln von Bedeutung sind.

**SCHLÜSSELWÖRTER**

Aerosol Inhalation; Atemwegsabscheidung; SPECT/CT; Tc-99m; Gezielte Impfstoff Anwendung; HPV
CORRESPONDING AUTHOR:

Prof. John O. Prior, PhD MD

Department of Nuclear Medicine and Molecular Imaging

Lausanne University Hospital

Rue du Bugnon 46, 1011 Lausanne, Switzerland

Tel. +41 21 314 43 48, Fax +41 21 314 43 49

john.prior@chuv.ch
INTRODUCTION

Vaccines constitute one of the most cost-effective preventive measures against illness and death from infectious disease [23]. Each year, five million people die worldwide from mucosally transmitted diseases that might be prevented by vaccines [8]. Cervical cancer is the second most common cancer in women in the world, the most common in Africa and the leading cause of cancer deaths in developing countries [4]. Vaccines against the leading HPV oncogenic types 16 and 18 are available with efficacy exceeding 95% in HPV-uninfected women [37]. However, efficient vaccination programs are difficult to implement in developing countries mainly because of currently prohibitive costs.

Despite the unprecedented medical success of vaccination, traditional application routes (intramuscular or subcutaneous) are not without limitations. In the context of mass vaccination campaigns in developing countries, needle-free vaccination can increase compliance (reduced local pain and side effects) and decrease overall costs (no need for needle disposal, etc.) Specific vaccine formulations abolish the need for a “cold chain” (specific equipment, and procedures to maintain vaccine at low temperatures until administration) [19,24,28] and aerosol immunization is such an alternative. This is offering many advantages: ease of application by paramedical personnel, lesser invasiveness favouring acceptance, reduced risk of cross-contamination by blood-born infectious agents, diminished
medical waste, and lower costs thanks to the use of multidose vials, among others [2,21]. Moreover, aerosol vaccination may induce better immunogenicity than conventional subcutaneous injections [8] because mucosal immune response might induce broader protection due to the production of IgA in addition to systemic IgG antibodies [30,39].

Nuclear medicine is a unique resource for the translational research about therapies delivered as aerosols. Indeed, for both research and development SPECT or PET of aerosol lung deposition is the most relevant strategy to pre-clinically assess the actual dose delivered to the target area [7,9,15]. At the time of translation to clinical trials, lung deposition imaging allows to optimize aerosol delivery to the target for immunization (central lung) while minimizing potential side effects due to deposition in less effective area (peripheral lung).

In a preclinical validation study in non-human primates, Corbett et al. [8] showed that aerosol-delivered poxvirus-based vaccination was safe, feasible, and immunogenic. The next step towards clinical implementation consists in validating this aerosol vaccination in humans. However, before dose escalation and safety analysis of side effects, more information needs to be collected about vaccinal particle charge and lung distribution during the face-mask aerosol nebulization [39]. Thus, the aims of our study were: (1) to assess the fraction of the nebulized particles delivered to the lungs to decide about the future viral charge; (2) to demonstrate a privileged
deposition of aerosolized particles into the central part of the lungs to elicit optimal immunological response, while limiting the alveolar exposure (not essential to proper immunization) and potential inflammation; and (3) to verify administration safety by quantifying environmental particle release.

**METHODS**

*Study population*

Healthy volunteers were prospectively recruited by advertisement at the Lausanne University Hospital, Switzerland. Before inclusion, they underwent history taking (personal medical history including pulmonary disease, infectious disease, smoking, asthma and chronic obstructive pulmonary disease) and a physical examination. Peak expiratory flow rate (PEFR) was measured immediately before and after inhalation as a simple surrogate for asthma detection and to detect any subclinical change due to the aerosol-induced broncho-constrictive reaction. Women of childbearing age underwent a pregnancy test; a negative result was required before inclusion. The Local Ethic Committee, the Swiss Federal Office of Public Health and Swissmedic approved the study protocol and participants signed a written informed consent form. Participants received a total effective dose of 1.9 mSv (1.0 mSv from the radiotracer and 0.9 mSv for the low-dose/slow-rotating CT) [36]. The radiation effective dose was obtained by
assuming that a maximum of 17% of the nebulized activity would be
distributed in the patient based on a preclinical study [26] and an effective
dose ED of 0.014 mSv/MBq computed from known organ distribution of
nanocolloid aerosol (Venticoll™, GE Healthcare Srl, Milano, Italy) and
ICRP 60 tissue weighting factors.

**Radiolabeling of particles and nebulization procedure**

The deposition procedure used non-viral, inert stannous chloride particles
(MTcK-2, Polatom, Otwork-Świerk, Poland) labeled with $^{99m}$Tc, with >90% of particles sized within 459–1110 nm (peaking at 788 nm) dispersed in a 4-
 mL buffer solution of identical physical and chemical characteristics as the
future vaccine but without immunogenic, sub-micrometric particles (Tris
buffer 1.2g/L, saccharose 50g/L, Na glutamate 1.87g/L, NaCl 2.9 g/L,
titrated with 5N HCl for pH 8.0). As previously described [26], aerosol
generated from such a formulation exhibits the same granulometry and lung
deposition pattern as the vaccine due to the low protein content. Labeling
was performed according to the manufacturer instructions [34]. Preliminary
measurements were conducted to verify labeling and particle size stability in
the buffer solution (pH 8) during nebulization (data not shown).

An ultrasonic nebulizer (Atomisor Megahertz AMGH, La Diffusion
Technique, St-Etienne, France) was used to create aerosol from radiolabeled
solution. Using a nebulization power set at 10/10, a 4.2 µm mass median
aerodynamic diameter (MMAD) aerosol was generated to favour central pulmonary distribution with care to prevent any temperature increase during sonication. To further privilege central pulmonary distribution of the aerosol, we chose active inhalation with disconnected internal ventilator and set tubing lengths 1 and 2 to get 75- and 300-ml buffer volumes, respectively (Figure 1A). For the inhalation process, the subject was placed in front of a biosafety cabinet containing a class-E12 HEPA filter, and equipped with a Double Mask system (Medicvent, Umeå, Sweden). The soft inner mask was connected to the nebulizer chamber and the hard outer mask evacuation outlet was connected to the biosafety cabinet aspiration through a separate HEPA filter to trap any aerosol particle escaping from the inner mask. The participants were instructed to freely inhale the nebulized aerosol in a controlled and reproducible tidal breathing manner for 10 minutes [27]. Residual activity in the nebulizer reservoir and tubing system was measured before and after the aerosol delivery. The activity released in the environment from the nebulization procedure was aspirated through the biosafety cabinet HEPA filter, whose activity was measured distant from the participant outside the administration room.

**Imaging acquisition and processing**

Twenty minutes after inhalation every participant underwent a SPECT/CT acquisition (Hawkeye IV, GE Healthcare, Milwaukee, MI) using an energy
window 140 keV±20%, 60 projections of 8 sec, a 128x128 matrix, and CT acquisition parameters: 140kV, 2.5mA, helical, pitch 1.5, slice thickness 5mm. Participants also underwent a whole-body planar scintigraphy in both anterior and posterior view 50 min post inhalation (scan velocity 10cm/min, 256×1024 pixel).

Raw data were processed on a dedicated workstation (Xeleris 3, GE Healthcare, Milwaukee, MI) by two experienced nuclear medicine physicians, in consensus. SPECT/CT images were reconstructed using 2D-OSEM (10th-order Butterworth, 0.5-cycle/cm cut-off frequency). Regions of interest (ROI) were drawn on whole-body anterior and posterior images around each lung and for the whole-body; counts were computed using geometrical mean. On tomographic images, volumes of interest (VOI) were drawn following anatomical boundaries provided by CT on separate transaxial slices centered on the hilum for 1-st order bronchi and applied to the reconstructed SPECT dataset. This allowed to separate central particle deposition (from carina to lobar bronchus division) from peripheral deposition (beyond lobar bronchus division) (Figure 3 A) and to compute the central-peripheral deposition ratio \( C/P = \frac{C}{P} = \frac{\text{COUNTS}_{\text{central}}}{\text{COUNTS}_{\text{peripheral}}} \). A semi-quantitative analysis to compute a scintigraphic \( C/P \) index was also performed to quantify the uptake in central bronchi as compared to pulmonary parenchyma on the SPECT transaxial slices using a 5-point Likert scale: \( C/P \) index = grade 0: no difference; grade 1:
questionable difference; grade 2: faint difference; grade 3: marked
difference; grade 4: very strong difference.

For quantifying total pulmonary particle deposition $TPD$, the
sensitivity of SPECT/CT was calibrated using a 200-mL reference phantom
containing 5MBq of $^{99m}$Tc-pertechnetate imaged using the same SPECT
acquisition and reconstruction parameters. This allowed computing the
activity deposited in the lung volume from the total counts. The percentage
of nebulized activity deposited in the lungs was then computed as $TPD (%)$
\[ = 100 \cdot \frac{COUNTS_{\text{lungs}}}{COUNTS_{\text{standard}}} \cdot 5 \text{ (MBq)} / \frac{Activity_{\text{nebulizer}} \text{ (MBq)}}{}, \]
Then, the absolute central pulmonary deposition $CPD$ can be derived as
\[ CPD = TPD \cdot \frac{[C/P]}{1 + [C/P]} \]. All measured activities were corrected for
the physical half-life of $^{99m}$Tc.

**Statistical analysis**

Continuous variables are presented as mean±SD or as median and 25th to
75th percentile interquartile range (IQR), and categorical variables are
presented as number and percentage. We used non-parametric Wilcoxon
rank sum test to compare continuous variables before and after the exam as
well as to compare variables according to gender and smoking status.
Association between variables was assessed using non-parametric Spearman
correlation coefficient ($\rho$). Statistical analyses were performed with Stata
12.1 software (Stata Corp., College Station, TX) and a $P$-value $<0.05$ was considered as statistically significant.

RESULTS

Population

Twenty-one healthy volunteers were enrolled and complete data were available in twenty participants (13 women, 7 men) aged 24±4 years. None had history of asthma or any other chronic or recent pulmonary condition; 5 were smokers (25%). Pulmonary auscultation was unremarkable in all participants and peak expiratory flow rate was within normal range for age and sex (Table 1).

Inhalation and procedure safety

The 10.0-min nebulization could be performed safely in all participants with an activity of 430±20 MBq of $^{99m}$Tc-colloid introduced in the nebulizer chamber. No participant experienced dyspnea during or after inhalation. No unexpected side effects or coughing were observed. Peak expiratory flow rate at the end of the study was identical to baseline ($P = 0.9$), also in subgroup analyses by gender and smoking status (Tab. 1). As expected, PEFR was significantly related to participants’ gender (−28% in women), height ($\rho = 0.78, P=0.0002$) and body surface area ($\rho = 0.69, P=0.001$).
The nebulization was also safe for the environment; no activity was released from the nebulization system or from the double mask in the biosafety cabinet HEPA filter. At the end of the inhalation, the nebulization system contained >90% of the activity, with the largest activity in the nebulization chamber (Fig. 1A and 1B).

**Inhaled particle distribution**

Whole-body scans revealed that inhaled particles were mainly localized in respiratory and digestive tracts, *i.e.* the mouth/oropharynx (*N* = 20), esophagus (*N* = 9), stomach (*N* = 17) and bowel (*N* = 13) due to saliva swallowing ([Figure 1C](#)). Of note, minimal activity could be seen in the bladder (*N* = 2, different than the one of Figure 1) and no activity was seen in the liver, spleen, kidney, thyroid or bone marrow.

On planar scintigraphy, lung activity represented 40±9% of the total whole-body activity. There was no difference according to gender (women 38±8% vs. men 43±11%, *P*=0.4) or to smoking status (non-smokers 39±10% vs. smokers 43±6%, *P* = 0.2). On SPECT images, 54±4% particles were localized in the right lung and 46±4% in the left lung (*P* < 0.0001). This relative distribution was neither influenced by gender (*P* = 0.7) nor by smoking status (*P* = 0.6). There was also no significant difference between upper, middle and lower third of lung fields (*P* > 0.6).
Total pulmonary deposition, $TPD$ was $1.3\pm0.6\%$ (range 0.4–2.6%) of the total activity initially present in the nebulizer (Fig. 2). Residual inhaled particles were also seen on SPECT/CT in the trachea ($N = 13$) and on the skin ($N = 9$) due to salivary contamination from the mouth after inhalation. There was no significant difference between men and women ($1.4\pm0.7\%$ vs. $1.2\pm0.6\%, P = 0.9$) or between smokers and non-smokers ($1.4\pm0.7\%$ vs. $1.2\pm0.6\%, P = 0.7$).

Regional lung distribution of inhaled particles

SPECT/CT showed a central to peripheral deposition ratio $C/P$ of $0.4\pm0.2$ (range 0.15–1.14) and a central pulmonary deposition $CPD$ of $0.3\pm0.3\%$ (range 0.1–1.4) (Fig. 2). An example is illustrated in Fig. 3, with VOI drawn for computing the central and peripheral activity. The $C/P$ ratio was not affected by the smoking status (non-smokers $0.36\pm0.11$ vs. smokers $0.51\pm0.36$, $P = 0.6$), but tended to be higher for women than men ($0.46\pm0.22$ vs. $0.30\pm0.11$, $P = 0.06$). Of note, $C/P$ ratio was significantly correlated with PEFR ($\rho = -0.58$, $P = 0.01$).

The semi-quantitative $C/P$ index showed a favourable central distribution with 11/20 (55%) of the participants showing a marked or very strong uptake and 15/20 (75%) showing a higher uptake in central regions than in parenchyma (grade 2 or above) (Fig. 4).
DISCUSSION

Thanks to the use of scintigraphic imaging to optimize the deposition within the central lung, preclinical studies of aerosol administration poxvirus-based vaccines in non-human primates have led to a safe and long-lasting immune response [8,26]. Here, we performed a proof-of-concept study in volunteers to assess the feasibility of aerosol nebulization, including the basic safety profile of non-vaccinal buffer solution at the individual and environmental level, and to quantify regional distribution. Our results demonstrate that quantification of the regional distribution of radiolabeled aerosols in a human vaccine model without immunogenic particles is feasible. Moreover, the administration is safe for the participants and the environment. These results are encouraging for future vaccine application trials in humans, where the full safety profile and immune response will be assessed.

Within the lung, several factors may influence the site of particle deposition, the size being one of the most important [18]. Particle sizes of 4–5 μm, such as the one produced in our study are thought to be optimal for a central deposition of an aerosol in the lungs [5]. The central lung is considered as the target area to elicit optimal immunological response [1,3,8,29,33]. The human upper airway mucosa contains a dense network of antigen-presenting cells throughout the nasal cavity, trachea, and lungs ready to initiate immune response when in contact with a microbial burden.
During inspiration, larger particles will be deposited merely in the tubing system and smaller ones in the peripheral part of the lung [2,6,10].

Planar gamma camera scintigraphy is well established for measuring deposition of radioaerosols [11,38]. SPECT /CT provides 3-dimensional, detailed information and offers a superior assessment of aerosol deposition [13,14,16]. In addition, we performed CT-based attenuation corrections of the SPECT images and used a calibration factor derived from a phantom to more accurately assess the activity deposited in target regions [27]. Our results support the feasibility of aerosol delivery of vaccines with preferred central lung distribution, in agreement with previous results in a series of 8 non-human primates [8].

The efficacy of inhaled drugs, whether given for treatment of lung disease [17,25,32,35] or to achieve an effect in some other part of the body, depends on drug deposition in the lungs. Our results with mean lung deposition \( TPD \) of 1.3±0.6% of the total nebulized activity were within range of values observed in the preclinical non-human primate study (3.6±1.1% and 1.8±0.5% for two different strains of poxvirus-based vaccine) [8]. Although this figure may seem low, it was sufficient to elicit durable vaccine immune response [8]. Similarly, our central-to-peripheral deposition ratio reached 0.4±0.2, close to the non-human primate preclinical values \( C/P = 0.75 \) in average) [8] and is in agreement with our previsions in order to limit exposure of alveoli to vaccinal proteins.
considering a potential risk of alveolitis. It is true that ultrafine aerosol-like deposition can reach up to 30% in a single-breath, but with a clearly alveolar distribution, which is not what is needed for the same reason (eventual risk of alveolitis). For the first clinical studies, these safety considerations have oriented our choice on this particular ultrasonic nebulizer despite a relatively low predicted efficiency for delivering the aerosol to the central airways. Following this modelization study, this device will allow to precisely deliver escalating doses for the assessment of both efficacy and safety of the vaccine.

A few limitations to our study need to be mentioned. This study was performed in healthy participants. However, in patients with airway disease, aerosol deposition can be different, namely with a more pronounced central deposition and a potentially faster washout of centrally deposited aerosols by mucociliary clearance or cough reflex [12]. However, this should not be a major problem in the proposed HPV vaccine model, as potential subjects would be young, non-HPV-exposed and devoid of lung disease. It is also worth mentioning that non-human primates were pre-treated with atropine not only to reduce salivation, but also to get transient inhibition of the bronchial mucociliary clearance and favour antigen presentation; thus, the effect of mucociliary clearance or its transient inhibition need obviously to be specifically studied. This was not done in this study on volunteers and could have influenced the results. Moreover,
non-human primate results were also developed using planar scintigraphy and there are known differences between regional pulmonary depositions measured on 2-D planar scans and 3-D SPECT [14]. Finally, the assessment of nebulized particles could also be performed by PET with several advantages over SPECT (absolute quantitation without the need of a calibration standard, shorter isotope half-life) [31] but the labelling of aerosols with positron emitters remains challenging. $^{13}\text{NH}_2$ has been employed to image saline-based aerosols but requires an on-site cyclotron[40]. Of note, the availability of $^{68}\text{Ge}/^{68}\text{Ga}$ generators may facilitate the use of PET in aerosol deposition research in the future with the possibility to directly use $^{68}\text{Ga}$ instead of $^{99m}\text{Tc}$ to label kit-based radiopharmaceuticals [22].

In conclusion, we demonstrated a feasible and safe method for aerosol delivery in humans of non-viral inert particles with identical physical and chemical characteristics as the future vaccine. Our study provides a bridge between in vivo preclinical testing and clinical trials, allowing the latter to be planned with increased confidence. The present work emphasizes the unique contribution of nuclear imaging in translational research for pulmonary delivery of active formulations administered as aerosols. Further studies will be needed to determine the optimal viral charge needed to guarantee the appropriate dose of active particles
deposited in the immunogenic central area and assess the immune response of aerosol vaccine.

ACKNOWLEDGMENT

The authors are indebted to Mr. Charles Schindler (Lausanne University Hospital Pharmacy) for preparing the buffer solution and to Logicair S.A. (St-Aubin, Switzerland) for the biosafety cabinet. The authors also wish to thank for their expert advices on aerosols Dr. Stéphanie Lerondel from the Centre for Small Animal Imaging at TAAM, CNRS (Orléans, France), and Dr. Laurent Vecellio from Aerodrug-DTF Medical (Tours, France) and INSERM U 1100/EA6305, University François Rabelais (Tours, France).

The financial support of the Department of Obstetrics and Gynaecology and Nuclear Medicine and Molecular Imaging (Lausanne University Hospital) are to be acknowledged. At the time of the study, J.O.P. was recipient of an Academic Research Award from the Leenaards Foundation (Lausanne, Switzerland).

DISCLOSURE STATEMENT

The authors declare that they have no conflict of interest.
REFERENCES


9. Corcoran TE. Imaging in Aerosol Medicine. Respir Care 2015; 60: 850-855; discussion 855-857


34. Polatom. Kit for the preparation of 99mTc-Colloid. 2009


FIGURES LEGENDS

Fig. 1. Distribution of the radiolabelled particles after nebulization. (A) Nebulization system (f = filter, m = mask; nc = nebulization chamber; 1 = 75-mL tubing; 2 = 300-mL tubing; *connected together during operation). (B) Corresponding planar scintigraphy of nebulization system. (C). Anterior and posterior whole-body planar scintigraphy showing particle distribution in the lung and mouth, oropharynx, trachea and stomach (s), but not in the thyroid, kidney, bladder, liver or spleen.
**Fig. 2.** Boxplot of the total pulmonary deposition (TPD), central pulmonary deposition (CPD) and central-to-peripheral distribution ratio (C/P) (N = 20). Boxes represent the limits of the 1st and 3rd quartiles, as well as the median; numbers represent the mean [95%CI]
Fig. 3. SPECT/CT imaging of particles deposition in the lung. (A) SPECT (first row) and SPECT/CT fusion (second row) images showing excellent central deposition. (B) Maximum intensity SPECT projection in anterior view. (C) Three-dimensional image rendering fusion of the airways on CT and SPECT activity showing central bronchial accumulation of inhaled particles.
Fig. 4. Scintigraphic index of central/peripheral distribution of inhaled particles. This histogram shows the best side’s uptake in central bronchi as compared to pulmonary parenchyma uptake on SPECT with an example of anterior view of the maximum intensity projection image for each class (grade 0 = no difference; grade 1 = doubtful difference; grade 2 = faint difference; grade 3 = marked difference; grade 4 = very strong difference). In total, 75% of the participants had a central/peripheral index of grade 2 or above (C/P ratio grade 2–4: 0.44±0.21 vs. grade 0–1: 0.22±0.12, P=0.02).
TABLES

Table 1. Peak expiratory flow rate at baseline and after inhalation (N=20)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Baseline</th>
<th>After inhalation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak expiratory flow rate [L/s]</td>
<td>8.1±1.7</td>
<td>8.0±1.3</td>
<td>0.9</td>
</tr>
<tr>
<td>Gender:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women (N=13)</td>
<td>7.1±0.7</td>
<td>7.1±0.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Men (N=7)</td>
<td>9.8±1.2*</td>
<td>9.6±0.5*</td>
<td>0.6</td>
</tr>
<tr>
<td>Smoking status:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-smoker (N=15)</td>
<td>8.1±1.8</td>
<td>8.0±1.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Smoker (N=5)</td>
<td>8.1±1.4†</td>
<td>8.2±1.2†</td>
<td>1.0</td>
</tr>
</tbody>
</table>

*Significant difference vs. women (P=0.0005 at baseline; P<0.0001 after inhalation);
†No difference vs. non-smokers (P=0.9 at baseline; P<0.7 after inhalation).